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There is no universally agreed-upon treatment for the fibrosis of scleroderma.
Recently, much information has been generated relating to the fundamental
mechanisms underlying this disease. Partly based on these observations, both
anti-inflammatory and anti-fibrotic agents have been considered as possible
therapies. However, this information has not been successfully translated into
clinical practice. In this issue, Pendergrass et al. use genome-wide expression
profiling to provide valuable insights into scleroderma. Previously, the authors
showed that morphea and ‘‘limited’’ scleroderma patients and a small subset of
diffuse scleroderma (dSSc) patients express an ‘‘inflammatory’’ profile, whereas
the majority of dSSc patients express a ‘‘fibroproliferative’’ profile. In the current
study, the investigators show that the gene expression profile of these patients is
fixed over time; i.e., in contrast to a previously held belief, the inflammatory
patients do not go on to become fibrotic, and vice versa. These data suggest that
expression profiling might be used to design clinical trials for scleroderma. The
inflammatory patients might be treated with anti-inflammatory agents, whereas
fibroproliferative patients might be treated with antifibrotic agents.
Journal of Investigative Dermatology (2012) 132, 1329–1331. doi:10.1038/jid.2012.67
A connective-tissue disorder of unknown
etiology, scleroderma (also called sys-
temic sclerosis or SSc), is a multisystem
disease characterized by the presence of
autoantibodies, vascular damage, and
organ fibrosis (Abraham and Varga,
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2005). A two-disease subset model,
consisting of limited scleroderma (lSSc)
and diffuse scleroderma (dSSc), is used
most commonly today (LeRoy and
Medsger, 2001). The systemic form is
characterized by diffuse skin involve-
ment and potentially severe internal
organ involvement. Conversely, loca-
lized scleroderma (which includes
morphea) is more common in children
and is usually confined to specific
regions of the body, with no internal
organ involvement.
There is no treatment for the fibrosis of
scleroderma, which can affect the skin
and internal organs and is a significant
cause of mortality, especially when lungs
are affected. Scleroderma is generally
thought to progress in phases: an earlier,
very active period, followed by a later,
slower-progressing period. In the case
of skin and lung, similar to tissue repair,
data have accumulated to support the
concept of an initial inflammatory process
that is followed by irreversible fibrosis
(Abraham and Varga, 2005).
Thus, two main subgroups of drugs
have been used to block progressive
disease: anti-inflammatories and anti-
fibrotics. It is generally considered that,
in the early stages, modification could
be possible by using immunomodula-
tory agents. Conversely, in patients
with rapidly progressive skin thicken-
ing (fibrosis) over the course of a few
months to a year, antifibrotic agents
might be more suitable. Compared with
10 years ago, we now have a better
understanding of some of the patho-
genic mechanisms that lead to sclero-
derma. For example, (non-canonical)
transforming growth factor (TGF)-b sig-
naling or endothelin-1 in lesional
(myo)fibroblasts is thought to be impor-
tant (Leask, 2008). However, the results
of clinical trials have been disap-
pointing. Although anecdotal results
have suggested that certain antifibrotics
(e.g., anti-TGF-b antibody, the endo-
thelin receptor antagonist bosentan, or
anti-inflammatory agents) may be effec-
tive in some patients, data often conflict
among treatment groups, and the results
of randomly controlled clinical trials
have been disappointing (Denton et al.,
2007; Giordano et al., 2010; Simms and
Lafyatis, 2010). A firm conclusion can-
not be reached until these agents are
applied to better-defined subsets of
patients or unless primary outcomes
take into consideration the hetero-
geneity of patients with scleroderma.
In this respect, unbiased molecular
profiling of patients is likely to be
informative. Genome-wide expression
profiling, in which tens of thousands of
genes are readily examined at one time,
is ideal to categorize the heterogeneity
in clinical presentations of scleroderma.
Indeed, earlier works by the Whitfield
group and collaborators have shown
reproducible, disease-specific gene
expression signatures in scleroderma skin
when compared with healthy controls
and have also shown that, surprisingly,
the disease-specific gene expression
profiles are shared by lesional and non-
lesional skin (Whitfield et al., 2003).
More recently, Whitfield and collabora-
tors analyzed the gene expression profile
of skin biopsy samples from 17 patients
with dSSc, 10 patients with lSSc and
morphea, and 6 healthy controls (Milano
et al., 2008). Cluster analysis of the
gene profiles derived from these biop-
sies revealed three groups: (1) a normal-
like group, which included the healthy
controls and some dSSc and lSSc patients;
(2) an inflammatory group, which inclu-
ded a small subset of dSSc patients as well
as patients with lSSc and morphea; and
(3) a diffuse-proliferation (fibrotic) group,
which was composed solely of dSSc
patients. Consistent with the notion that
TGF-b signaling and its downstream
mediator endothelin-1 contribute to the
fibrosis in scleroderma (Leask, 2008), the
diffuse-proliferation group had profiles
that were quite similar to the genes that
are induced in normal fibroblasts in
response to TGF-b (Sargent et al., 2010).
Pendergrass et al. (2012) combined
samples from 22 patients with dSSc and
9 healthy controls with the previously
reported samples. Analysis of these data
reveals that the aberrant gene expression
patterns are established early in the
disease and that they remain stable
during disease progression; i.e., the con-
cept that patients with ‘‘inflammatory’’
disease go on to become ‘‘fibrotic,’’ and
vice versa, was not supported by the
data. Moreover, although patients did
not appear to move between subsets
over time, patients within each subset
showed changes only in the intensity
of the signatures over time.
These data are exciting because they
suggest new ways of treating patients.
First, the gene expression data are likely
to be useful as surrogate outcome mea-
sures and to identify patients who are likely
to respond in clinical trials. Second, these
data suggest a plausible explanation for the
apparent disconnect between the excellent
recent progress in basic research in scler-
oderma and the disappointing clinical
results in which patients with different
gene expression subsets have been lumped
together. Finally, these data have funda-
mental importance for the future: anti-
inflammatory approaches would be best
suited for morphea and lSSc patients (and
a small subset of dSSc patients), whereas
antifibrotic approaches would be best
suited for a majority of dSSc patients.
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Clinical Implications
 Basic research has not yet been translated into clinical benefit for
patients with scleroderma.
 Patients with ‘‘localized’’ and ‘‘limited’’ (and some with diffuse) sclero-
derma show an ‘‘inflammatory’’ expression profile, whereas the majority
of patients with diffuse disease show a ‘‘fibrotic’’ expression profile.
These profiles are stable over time.
 Clinical trials might be designed wherein patients with inflammatory
signatures are treated with anti-inflammatory agents and those with
fibrotic signatures are treated with antifibrotic agents.
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